Pacira BioSciences Successfully Transitions PCRX-201 To A Scalable Commercial Manufacturing Process In The U.S.; Topline Data From Part A Of Phase 2 ASCEND Study Remains On Track For End Of 2026

Pacira Biosciences Publishes 2-Yr Phase 1 Results In Annals Of Rheumatic Diseases For PCRX-201 Gene Therapy In Moderate To Severe Knee Osteoarthritis, Showing Tolerability And Improvements In Pain, Stiffness, And Function

— A single locally administered intra-articular injection of PCRX-201 into the knee was well tolerated in patients with moderate-to-severe knee osteoarthritis —— Exploratory clinical outcome measures showed improvements

Pacira BioSciences shares are trading lower after the company lowered its FY2026 sales guidance.

RBC Capital Maintains Sector Perform on Pacira BioSciences, Raises Price Target to $25

RBC Capital analyst Douglas Miehm maintains Pacira BioSciences (NASDAQ:PCRX) with a Sector Perform and raises the price target from $24 to $25.

Needham Maintains Buy on Pacira BioSciences, Raises Price Target to $33

Needham analyst Serge Belanger maintains Pacira BioSciences (NASDAQ:PCRX) with a Buy and raises the price target from $32 to $33.